Document Actions
Count what is countable. Measure what is measureable.
What is not measureable, make measureable.
-- Galileo
BioPredictive presentation
The objective of BioPredictive is to discover and develop non-invasive diagnostic tests in order to faciltate the management and treatment of patients.
After the launch of FibroTest-ActiTest in 2002, which has since become the reference standard of non-invasive diagnostic tests, BioPredictive continues to innovate with the new tests, SteatoTest, NashTest, AshTest and FibroMax.
A technology available worldwide
Our tests are available worldwide. Most countries have a BioPredictive distributor.
Consult the regional distributors
list
Key figures
BioPredictive's activity has been consistently increasing from the beginning.
Patents
All of the BioPredictive tests are protected by the world patents.
The company BioPredictive was created in 2002 in order to ensure the development and marketing of FibroTest according to the terms of the exclusive licensing contract signed with APHP, holder of the world patents of FibroTest and beneficiary of the royalties.
Partners
BioPredictive and its scientific partners
History of the company
- 2001
- First scientific publication in The Lancet - read article
- 2002
- Founding of the company
- Signature of the contract license with the Public Assistance Hospitals of Paris (APHP), holder of the world patents protecting FibroTest, Actitest, SteatoTest, NashTest and AshTest.
- ANVAR (French national agency for innovation in research) prize winner
- First two diagnostic tests put on the market: FibroTest and ActiTest
- 2003
- Distribution of FibroTest-ActiTest in Europe
- Signature of many hospitals in France
- 2004
- Launching in the USA in partnership with Labcorp under the trade name, FibroSure
- 2005
- FibroMax, a package of 5 diagnostic tests, put on the market: SteatoTest, NashTest and AshTest complete FibroTest and ActiTest for an overall package.
- 2006
- Over 500 user laboratories in France
- Over 60 equipped hospitals in France
- 2007
- BioPredictive spreads to the EAst through the implementation of a new distribution network based in Russia and Ukraine.
- 2008
- Over 350,000 tests done since the launch
- 98 published scientific articles (available on the website)